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Abstract 
Protein stability is the most crucial factor in protein pharmaceutical preparations. Various 
techniques were applied for producing stable protein formulations such as spray-drying and 
freeze-drying. However, heating and freezing stresses are disadvantages for proteins using 
these methods, respectively. Accordingly, excipients have been used to preserve therapeutic 
effects of proteins during processing and for long period of time. Therefore, influences of 
Copovidone, Eudragit® RL-PO and Kollicoat® MAE-30 DP (as excipients) on stability and 
integrity of lysozyme (as a model protein) in spray-dried and freeze-dried forms were 
investigated. Protein formulations in both dried forms were prepared without and with the 
addition of mentioned excipients at different concentrations. Protein formulations were 
characterised for yield determination, morphology using scanning electron microscopic 
(SEM), thermal analysis by Differential Scanning Calorimetry (DSC), secondary structure 
stability using Fourier transform infrared (FT-IR) spectroscopy and biological activity. All 
protein formulations were subjected to a stability study as solid protein formulations for 3 
weeks at 24 °C/76% relative humidity and aqueous protein samples were stored at 50°C for 
30 minutes in a water bath. Results showed that Copovidone successfully preserved integrity 
and biological activity of lysozyme before and after storage in both spray-dried and freeze-
dried forms with more advantage for using higher concentration of the same excipient. 
Smooth spheres of spray-dried lysozyme formulations with Copovidone were smaller than 
spray-dried lysozyme without and with Kollicoat® MAE-30 DP, which affected %yield 
produced. Copovidone has demonstrated valuable protection ability for lysozyme. 
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 Introduction 1 
Among all of the biological macromolecules, proteins embrace an exceptional heterogeneous 2 
class. Protein-based therapeutics has found to be an effective treatment for wide spectrum of 3 
diseases (1), e.g. diabetes, infections, inflammation, wound healing, decubital ulcers, sunburn 4 
etc. However, protein therapeutics suffers from the inadequate stability, especially in aqueous 5 
form (2), as a result of protein aggregation by the effect of protein unfolding or surface 6 
interaction between the hydrophobic residues within the proteins (3). This is consider the 7 
major drawback of such a drug. Proteins are marginally stable in solid form but prone for 8 
physical degradation.  9 
 10 
Several methods were applied in order to overcome the challenges associated with protein  11 
stability. The most frequently used method to produce solid state protein formulations with a 12 
considerable stability is spray drying (see for example, (2,4,5) and freeze drying (see for 13 
example, (6-8). Another method used to stabilise proteins is by adding wide variety of 14 
excipients to stabilise proteins (see for example, (2,9,10). 15 
 16 
Spray drying is a one-step liquid atomization technique wildly used to produce solid 17 
pharmaceutical dosage forms. This process can utilise micro- and nano-size scaled particles 18 
that are suitable for pulmonary administration (2).  Protein spray-dried particles prepared 19 
using this technique were developed either alone or with the addition of some stabilising 20 
excipients. So far, different excipients were used in order to obtain a stable protein 21 
formulation using spray drying method include sugars (e.g. trehalose (10)), surfactants (e.g. 22 
pluronic F-127®(2), polyols (e.g. sorbitol (11)), polymers (e.g. dextran and polyethylene 23 
glycol (12)), antioxidants (e.g. ethylenediaminetetraacetic acid (13)), amino acids (e.g. 24 
ascorbic (13)), chelating agents (e.g. ammonium sulphate (14)).  25 
 26 
Freeze drying method is a sublimation based technique commonly used for heat sensitive 27 
materials to increase their stability and shelf life as pharmaceutical products. This technique 28 
involves two steps: freezing and drying. A drastic reduction in the hydration of the proteins is 29 
a major denaturation factor in freeze drying process (15). Proteins are labile molecules that 30 
need to preserve their moisture content at certain level to ensure conformational structure and 31 
biological activity stability. However, in order to ensure long term stability of protein 32 
pharmaceutical preparations, the moisture level shouldn’t exceed 9% which is enough to 33 
hydrate the active site cleft of the proteins (16). Some excipients has cryoprotective and 34 
lyoprotective properties accordingly used to stabilise proteins in freeze drying process (see 35 
for examples; hydroxyethyl cellulose used with lactate dehydrogenase (17), polysorbate 20, 36 
PǾÑOMÕŎŒÑÆ ̆-cyclodextrin and hydroxylethyl starch with glucagon (18), trehalose with insulin 37 
(19), pluronic F68 with calcitonin (20) and maltotriitol, trehalose, maltitol, and lactitol with 38 
L-lactate dehydrogenase and bovine serum albumin (21). 39 
 40 
The mechanism by which all of the additives works is not very clear. However, there are 41 
some suggested mechanisms: (i) excipients can replace the intermolecular interactions of 42 
water within the protein by the effect of dehydration, (ii) hydrating the active site cleft of the 43 
protein accordingly provide a good substrate (2,16) and (iii) direct interactions with the 44 
protein active site that assess reducing the potential energy of the protein by mutual exclusion 45 
of the hydrophobic residues of the protein exposed to the aqueous environment (2, 22) and 46 
(iv) vitrification (the formation of amorphous glass) that hinder any molecular motion and 47 
inhibit any kind of  interactions between proteins which could lead to aggregation.   48 
 49 
 50 
The purpose of this study is to investigate the effects of three copolymers named 51 
(Copovidone, Eudragit® RL PO and Kollicoat® MAE 30 DP) on spray-dried and freeze-52 
dried lysozyme (as a model protein) thermal stability, integrity and biological activity before 53 
and after storage. Both drying processes were chosen for subjecting the protein to two 54 
different drying conditions using high temperature (during spray drying) and low temperature 55 
(during freeze drying). Copovidone is a copolymer of 1-vinyl-2-pyrrolidone and vinyl acetate 56 
(60:40 ratio). It is used in cosmetic and pharmaceutical preparations as a tablet binder, form a 57 
protective layer in film coating on tablets, film-forming agent in spray and effective in 58 
controlled drug release formulations. This excipient has a stabilising effect on lysozyme in 59 
aqueous media (23), however, its effect on lysozyme in dried forms is still unknown. 60 
Eudragit® RL PO is a copolymer of ethyl acrylate, methyl methacrylate and a few content of 61 
methacrylic acid ester with quaternary ammonium groups (as salts) that makes the polymer 62 
permeable (24). It’s usually used for sustained release drug delivery. Kollicoat® MAE 30 DP 63 
is a methacrylic acid-ethyl acrylate (1-1 mass proportion) copolymer used as a film-former in 64 
enteric coatings. Therefore, those polymers are worth investigation on protein stability. 65 
Kollicoat® MAE 30 DP and Eudragit® RL PO were also used as most of copolymers have 66 
high potential to stabilise proteins. Lysozyme (a globular protein) was selected as a model 67 
protein as it is well characterised in the literature (for example 25, 26). Also, it was used due 68 
to its bacteriostatic and bactericidal activities, lysozyme is used in pharmaceutical industry 69 
(27) and food industry (28). Lysozyme was also found to have an inhibitory effect on HIV 70 
growth in vitro (29). The approach used in this study may be feasible to be applied to other 71 
proteins with lower thermal stability, to confirm this concept; trypsin has been used in this 72 
research to study its biological activity in the proposed formulations. 73 
 74 
Materials and methods 75 
Materials 76 
Lysozyme was purchased from BBI Enzyme Ltd, UK. Copovidone, Micrococcus 77 
Lysodeikticus (lyophilised cells), sodium chloride and Sodium acetate anhydrous were 78 
obtained from Sigma-Aldrich, UK. Kollicoat® MAE 30 DP was purchased from BASF, 79 
Germany. Eudragit® RL PO was obtained from Rohm GmbH, Chemische Fabrik, Germany. 80 
Sodium hydroxide was purchased from BDH Chemical Ltd, UK. Potassium dihydrogen 81 
phosphate was purchased from Fisher Scientific, UK. Distilled water.  82 
Preparation of spray-dried protein 83 
Aqueous protein solutions (1%, w/v) were spray-dried without and with excipients 84 
(Copovidone or Kollicoat® MAE 30 DP) via a BÜCHI Mini Spray Dryer B-290. Excipients 85 
were used at different concentrations (the choice was based on some literature see for 86 
example Haj-Ahmad et al., 23) as follows: 0.2 and 0.5 % (w/v) of Copovidone and 2 and 4 % 87 
(v/v) of Kollicoat® MAE 30 DP dispersion (metha-acrylic acid: ethyl-acrylate copolymer 1:1 88 
dispersion 30%). Solid proteins are known to be stabilised by excipients such as salts, sugars 89 
and polymers (30). Hence, the chosen copolymers were used in low concentrations ranging 90 
from 0.2% to 4% to study the sensitivity and response of dried lysozyme formulations to the 91 
stabilising effects, if there is any, of the small amounts of the used excipients. Protein 92 
solutions were filtered using 0.2 ȝÖ FÑÕÕÞÕŎŒÑ ÍÒPǾMPÑ ÌÑÖNǾMŌÑ ĞÒÕPÑǾŒ ĂJOMPÖMŌ 93 
International Ltd.). The feed solution passed through a silicone tubing of inner diameter of 4 94 
mm and peristaltic feed pump (35%) to an atomizing nozzle (0.7mm diameter) at rate of 95 
7 ml/min and compressed air at rate of 600 l/h. Solutions were sprayed inside a glass chamber 96 
at an inlet temperature of 110± 4 °C and outlet temperature was 55 ± 3 °C. Cooling water was 97 
circulated through a jacket around the nozzle to minimise the heat stress effect on the 98 
proteins. Spray-dried particles were collected by a high-performance cyclone separator and 99 
were stored tight in vials at 3-4 ň°C until further analysis. 100 
Preparation of freeze-dried protein 101 
Aqueous protein solutions (1%, w/v) were freeze-dried without and with (0.2 and 0.5 % 102 
(w/v)) Copovidone, (0.2 and 0.5 % (w/v)) Eudragit® RL PO and (2 and 4 % (v/v)) 103 
Kollicoat® MAE 30 DP. Freeze drying was performed using VirTis Benchtop Freeze Dryer 104 
Biopharma, USA. Two millilitres of protein formulations were filled into 5 mL glass vials. 105 
Solutions were let to freeze at -ÐD ÛF ŅŎǾ Ç hr followed by lyophilisation for 48 hours at a 106 
pressure of 10mBar, condenser temperature of -ĈĆĆ  Č ÛF and shelf temperature of 21 ÛF. 107 
Shelf temperature was kept MP ČĈ ÛF ŇÞǾÒŌŊ the whole freeze drying process; meaning that 108 
protein samples were dried using primary drying step in which the sublimation of ice takes 109 
place and continuous vapour removal occurs due to the difference in vapour pressure of the 110 
samples compared to that of the condenser. The condenser temperature was set at low 111 
temperature (-ĈĆĆ ÛF) to allow for low residual moisture content (30). Hence, the secondary 112 
drying NŘ ÒŌŃǾÑMŒÒŌŊ POÑ ŒOÑÕŅ PÑÖŐÑǾMPÞǾÑ MNŎQÑ ČĈ ÛF has not taken place as it may lead to 113 
removal of essential bound water (by desorption) which may be crucial to proteins’ activity 114 
(16), nevertheless the effect of moisture on proteins is complex (30). The freeze-dried 115 
products were kept at 3-D ÛF ÒŌ ŇÑŒÒŃŃMPŎǾŒ ŃŎŌPMÒŌÒŌŊ ŒÒÕÒŃM ŊÑÕ ÞŌPÒÕ MŌMÕŘŒÒŒB  116 
Characterisation of spray-dried and freeze-dried protein preparations 117 
Determination of percentage yield 118 
The % yield was determined by defining the final weights of the prepared spray-dried protein 119 
particles. Then, % yield was calculated using the following equation: 120 
% Yield= (Final protein weight)/(initial protein weight) *100                                        (Eq.1) 121 
Microscopic examination of spray-dried and freeze-dried lysozyme formulations 122 
The morphologies of the spray-dried and freeze-dried protein particles were inspected using 123 
scanning electron microscope (SEM) (Hitachi S3000-N variable pressure scanning electron 124 
microscope, Japan). Small quantity of the dried protein preparations were attached to a 125 
double-sided carbon tape (Agar Scientific, Stansted, UK), positioned on an aluminium stub. 126 
The samples were coated with a mixture of gold/palladium using a Quorum Technology 127 
(Polaron Range) SC760 by exposing samples to an Argon atmosphere at about 10í1 mbar or 128 
10 Pa. Samples were coated for 2 × 105 s.  129 
Structure analysis using Fourier Transform Infra-Red (FT-IR) Spectroscopy 130 
FT-IR spectroscopy was carried out using a Perkin–Elmer FT-IR Spectrum BX series 131 
(Beaconsfield, Buckinghamshire, UK) equipped with PIKE MIRacleTM detector. A small 132 
quantity of dried protein sample was loaded into the system. Peaks positions were detected 133 
using Spectrum BX series software version 2.19. The FT-IR spectra were recorded for 134 
protein samples and excipients, after subtraction of the background from 4000 to 550 cmí1 at 135 
4 cmí1 resolution for an average of 25 scans. 136 
Thermal analysis of spray-dried and freeze-dried protein samples 137 
The thermal stability of lysozyme in all formulations was assessed in solid form by 138 
Differential Scanning Calorimetry  (DSC). Freeze-dried and spray-dried protein samples 139 
were thermally analysed using DSC Q1000M TA instrument, England. Pure indium standard 140 
was used to calibrate the DSC instrument. Unprocessed, spray-dried and freeze-dried solid 141 
protein formulations (in the range of 2-4mg) were loaded into hermetically sealed pans. The 142 
pans were then loaded under nitrogen at a flow rate of 50ml/min. The pans were scanned 143 
from 0 °C to 300 °C at a rate of 10.0 °C/min. The thermographs were normalised in counter 144 
to lysozyme weight. All samples were analysed in triplicate.  145 
 146 
 147 
Biological activity assay for lysozyme 148 
The activity of lysozyme, in triplicate, was evaluated by monitoring the rate of hydrolysis of 149 
̆-1,4-glycosidic linkages between N-acetylglucosamine and N-acetylmuramic acid in 150 
bacterial cell walls by lysozyme (28). The bacterial suspension of Micrococcus Lysodeikticus 151 
(20%) was prepared in 90 ml phosphate buffer 0.067 M, pH 6.6, at 25 °C and 10ml of 1% 152 
sodium chloride (NaCl). Enzymatic solutions (15 ȝŊCÖÕÅ ŎŅ ÞŌŐǾŎŃÑŒŒÑŇÆ ŒŐǾMŘ-dried and 153 
freeze-dried lysozyme without and with excipients were prepared using the same buffer. The 154 
biological reaction was initiated by adding 0.5 ml of each enzymatic solution to 2.5 ml of the 155 
bacterial suspension. The unit activity of lysozyme is well-defined as the total amount of 156 
lysozyme that decrease the absorption rate at of the system at Ȝ 450 nm by 0.001 miní1 at 157 
24 °C. M501 Single beam Scanning UV/Visible spectrophotometer Camspec (Biochrom, 158 
UK) was used to monitor lysozyme activity. The activity was calculated from the following 159 
equation (31).  160 
ĖŃPÒQÒPŘĂĮŌÒPŒCÖŊÅĚǻÇDĆŌÖCÖÒŌCĆBĆĆĈîÖŊ enzyme in the reaction                         (Eq.2) 161 
Effect of heating (at 50°C) and relative humidity (75% RH) on lysozyme activity   162 
Effect of stress conditions of high temperature and high RH on lysozyme formulations has 163 
been investigated. Accordingly, aqueous protein formulations were kept at DĆ ࡈ C for 30 164 
minutes in a water bath. Solid protein samples were kept at accelerated conditions of 76% 165 
relative humidity (RH) at 24 °C for three weeks. Samples were assessed post-storage for 166 
enzymatic activity (which considered the main effective test to investigate efficacy of the 167 
formulated enzyme) and the results were compared with the pre-storage samples.  168 
Statistical analysis 169 
The generated data were statistically analysed using SPSS®. Post Hoc test was used if data 170 
was normally distributed and Mann Whitney Test was used as non-parametric test if the data 171 
was not normally distributed. The P-value of less than 0.05 was considered as a significant 172 
level.  173 
Result and discussion  174 
Determination of percentage yields for spray-dried proteins 175 
Spray drying was performed for lysozyme without and with Copovidone and Kollicoat® 176 
MAE 30 DP (Fig 1). No spray drying was performed for samples containing Eudragit® RL 177 
PO (Fig 1) due to insolubility of this excipient in liquid phase at room temperature (22ŰC) 178 
due to the presence of the salt quaternary ammonium groups in its structure (32). 179 
Table 1 shows the percentage yields of spray-dried lysozyme formulations in absence and 180 
presence of excipients (Copovidone and Kollicoat® MAE 30 DP). All spray-dried 181 
formulations had more than 60% of yield although 30-40% of product yield is typically 182 
expected by using bench-top spraying system (33), however in pharmaceutical industry, the 183 
large scale production for spray dried pharmaceutical products is feasible and hence using a 184 
large scalable spray drier can lead to a highest possible yield. Spray drying of lysozyme with 185 
Copovidone (0.2 and 0.5% w/v) shows the lowest %yield and this is due to the small size of 186 
the spray-dried particles in this formulation as compared with spray-dried lysozyme and 187 
spray-dried lysozyme with Kollicoat® MAE 30 DP. Copovidone has a relatively high glass-188 
transition temperature (103-106 °C) that aids in fabricating small particle size. Spray drying 189 
system suffers from the inefficient particle collection of the small size particles that has a 190 
high impact on the %yield of the last product (2). Accordingly, particles with low density 191 
might be drawn up into the vacuum of the spray dryer (34). Fig 2 shows the big particle size 192 
of spray-dried lysozyme with Kollicoat® MAE 30 DP. This can also justify the highest (~ 193 
70%) % yield in this formulation and the potential of the cyclone separator to capture the 194 
large size particles, therefore increasing the %yield. Kollicoat® MAE 30 DP is a copolymer 195 
which is designed for enteric tablet coating. During the spray drying process, this copolymer 196 
reduced the chance of the spray-dried particles to stick to the chamber walls and the cyclone 197 
separator of the spray dryer system. Thus, resulted in the highest spray-dried percentage yield 198 
for lysozyme samples.  199 
Insert Fig 1 and Table 1 200 
 201 
Microscopic examination of spray-dried and freeze-dried protein particles 202 
 203 
The morphology of the protein solid formulations can be affected by the type of the used 204 
excipients and the applied processing technique. Fig 2 shows some selected SEM images of 205 
spray-dried and freeze-dried lysozyme formulations. Spray-dried protein particles were 206 
uniform, smooth and spherical architectures as compared with freeze-dried structures. 207 
Different types of additives were used, different effects on the morphology of the protein 208 
were observed. 209 
Spray drying of lysozyme without excipients led to hollow spherical structures which 210 
remained the same when Kollicoat® MAE 30 DP was added. However, hollowness were 211 
disappeared when lysozyme was spray-dried with Copovidone. This shows that Copovidone 212 
has an effect on particle shape and density when spray-dried with the protein. 213 
The morphology of spray-dried particles has a significant role in the aerodynamic properties 214 
and performance of aerosol applications (2). Prinn et al. (34) suggested four different 215 
morphologies of the spray-dried particles; (I) smooth spheres (such as some of the spray-216 
dried lysozyme particles without excipients and most of spray-dried lysozyme particles with 217 
Copovidone) which are more preferable than other shapes as they can enhance the 218 
aerodynamic aerosol performance), (II) collapsed or dimpled particles (such as few particles 219 
of the spray-dried lysozyme with no excipients and most of the particles of spray-dried 220 
lysozyme with Kollicoat® MAE 30 DP) (III) particles with a ‘raisin like structure’ and (IV) 221 
highly crumpled and folded particles (34).  222 
Different factors have impacts on the morphology of spray-dried particles, particularly the 223 
rate of drying, as faster drying would most likely to produce dimpled dried particles. 224 
Subsequently, rapid evaporation of the liquid from the centre of the spherical particle/droplet 225 
results in holes if the surface is solid and crusty, unless water can escape by diffusion (35). In 226 
this study, the inclusion of Copovidone has improved the morphology of the spray-dried 227 
protein particles. Copovidone might replace protein components at the droplet surface before 228 
drying, accordingly, preserve the surface integrity of the spray-dried particles. Moreover, 229 
Copovidone could diffuse the water out slowly and avoid protein denaturation by slowing 230 
down the rapid dehydration of the protein. Copovidone’s ability to improve protein’s stability 231 
was clearly demonstrated by the biological activity assay results.   232 
Regarding freeze-dried protein formulations, the morphology of freeze-dried protein particles 233 
is usually structured at the primary drying stage in the freeze drying process. Freeze-dried 234 
lysozyme without excipients had relatively smooth surface, whereas freeze-dried protein in 235 
combination with Eudragit® RL PO had very different, rough and very porous surface with 236 
irregular morphology. Porous structure has higher surface area therefore may result in more 237 
protein-oxygen contact which can provoke the oxidative degradation of the protein (36). 238 
However, porous structure embraces a low density that can be an advantage for particles aim 239 
for inhalation delivery if the particle size is controlled (37). When added as an excipient to 240 
lysozyme, Copovidone resulted in the smoothest structure surface with no signs of crystals. 241 
Accordingly, Copovidone have significantly reduced the crystallinity of lysozyme which was 242 
also confirmed by DSC results. This indicates that lysozyme:Copovidone (1:0.2) formulation 243 
produced amorphous structure. Eudragit® RL PO and Kollicoat® MAE 30 DP did not 244 
produce smooth surface and had an adverse effect on the biological activity of lysozyme (as 245 
will discuss later).   246 
Insert Fig 2 247 
Differential Scanning Calorimetry (DSC) 248 
Thermal profiles of unprocessed, spray-dried and freeze-dried protein samples are shown in 249 
Table 2 which represent heat flow as a function of temperature and show the apparent 250 
denaturation temperature (Tm) values of unprocessed and processed protein without and with 251 
excipients. All of the DSC thermogram scans are characterised by two or more endothermic 252 
peaks. One broad endothermic peak, around 100-130 oC, which is related to water content of 253 
lysozyme samples (28) and thus might give an indication about the water content within each 254 
formulation (10). The second endothermic peak with varying broadness, around 180-202 oC, 255 
the peak maximum was considered to represent the apparent denaturation temperature of the 256 
protein in the formulations (Tm).  257 
 258 
 259 
                 260 
Insert Table 2 261 
 262 
Drying processes (spray drying and freeze drying) of lysozyme led to a small reduction (by 263 
about 1 ºC) of lysozyme apparent denaturation temperature as compared with the 264 
unprocessed lysozyme. A marked reduction of lysozyme’s apparent denaturation temperature 265 
was observed upon the addition of all excipients (Copovidon, Kollicoat® MAE 30 DP and 266 
Eudragit® RL PO). For spray-dried and freeze-dried lysozyme formulations with 267 
Copovidone, a significant (P<0.05) reduction of Tm was observed upon increasing the 268 
Copovidone weight from 0.2 to 0.5% w/v (by ~10 ºC). Moreover, there was an increase in the 269 
intensity of the endothermic water peak (first endothermic peak) in spray-dried samples of 270 
the lysozyme with Copovidone. This could be an indicative sign of the increase in water 271 
content in these formulations which might be due to the hygroscopic property of Copovidone 272 
which, in some instances, is considered as Copovidone’s limitation in its use that can affect 273 
the product stability in humid conditions. However, this can be overcome by a proper sealing 274 
and packaging of the final product. Spray drying and freeze drying of lysozyme with 275 
Kollicoat® MAE 30 DP showed a significant (P<0.05) reduction of the apparent denaturation 276 
temperature of lysozyme with more reduction for samples with higher ratio of Kollicoat® 277 
MAE 30 DP (refer to Table 2). The thermal stability of lysozyme with Eudragit® RL PO was 278 
significantly (P<0.05) higher than dried lysozyme samples with Copovidone and Kollicoat® 279 
MAE 30 DP. A third endothermic peak was observed for freeze-dried lysozyme with 280 
Kollicoat® MAE 30 DP or Eudragit® RL PO around 222-224 ºC which might indicate 281 
decomposition of the formulations at this range of temperature. 282 
 283 
The addition of the used excipients to the formulations led to broadness of the second 284 
endothermic peak as compared to unprocessed lysozyme (as received) which indicates a 285 
decrease in the crystallinity (38). This is further confirmed with surface morphological 286 
structures of the samples (absence of crystal structures) under SEM.  287 
Fourier Transform Infra-Red (FT-IR) spectroscopy 288 
Infrared spectroscopy was used to determine the secondary structure of lysozyme and 289 
whether or not the used excipients (Copovidone, Kollicoat® MAE 30 DP and Eudragit® RL 290 
PO) managed to stabilise lysozyme conformational structure throughout the drying processes.  291 
The secondary structure of proteins can be detected in the IR region of Amide I vibration 292 
(contributed to C=O stretching band with some contributions from CN stretching and CCN 293 
deformation) which can be detected in the range of 1600-1700 cm-1. Amide II vibration 294 
(contributed to the N-H bending vibration and C-N stretching) can be detected at the range of 295 
1500-1600 cm-1 (39-40).  FTIR spectroscopy analysis of lysozyme formulations was 296 
conducted within the range of 1800 – 900 cm-1. Fig 3 shows FT-IR spectra for unprocessed, 297 
spray-dried and freeze-dried lysozyme formulations.  298 
      Insert Fig 3 299 
Unprocessed lysozyme (as received) had Amide I and II peaks at 1645 and 1538 cm-1, 300 
respectively. The biggest shift (+14cm-1) of Amide I peak was found for freeze-dried 301 
lysozyme: Eudragit® RL PO (1:0.5 weight ratio) sample (Fig 3j) as compared to the control 302 
lysozyme spectrum (Fig 3a). This was considered as the biggest change. Therefore, +/- 1cm-1 303 
was considered as minor shift and anything more than that was considered as major shift in 304 
peak position (28). Freeze drying of lysozyme without any excipient preserved the secondary 305 
structure and conformation integrity of lysozyme to a great extent in both Amide I and II 306 
bands (Fig 3c). Whereas, spray drying of lysozyme without excipients (Fig 3b) disturbed the 307 
secondary structure of lysozyme as there were major changes in the shapes and shifts in both 308 
Amide I and II bands. This was also confirmed by the biological activity results. A significant 309 
(p<0.05) reduction of the biological activity of lysozyme in the spray-dried sample 310 
(89.4±5.2%) was observed; while 99.4±3.9% activity of lysozyme was maintained by freeze 311 
drying of lysozyme sample with no excipients.  312 
Freeze drying of lysozyme with Copovidone at two different concentrations (0.2 and 0.5% 313 
w/v) (Fig 3g,h, respectively), preserved the secondary structure and conformation integrity of 314 
lysozyme. However, spray drying of lysozyme with Copovidone (0.2 and 0.5% w/v) revealed 315 
major shifts of Amide I band by +6cm-1 (Fig 3d,e, respectively). From the above, it can be 316 
concluded that spray drying as a process for protein drying and without any excipients led to 317 
perturbation of the protein secondary structure. 318 
Freeze-dried samples of lysozyme:Eudragit® RL PO (1:0.5) and lysozyme:Kollicoat® MAE 319 
30 DP (1:4) showed major disruption of lysozyme secondary structure which is due to major 320 
shifts in both Amide I and II bands and this was combined with a significant (p<0.05) 321 
reduction of lysozyme biological activity in these samples, see below for protein biological 322 
activity results. This means that the above excipients at the mentioned concentrations 323 
triggered some sort of conformational changes to the secondary structure of the protein, 324 
accordingly, reduced the protein activity. In contrast, by using a lower concentration of 325 
Kollicoat® MAE 30 DP (in 1:2 lysozyme: Kollicoat® MAE 30 DP sample), freeze-dried 326 
lysozyme:Kollicoat® MAE 30 DP (1:2) resulted in major shift only at amide I band, 327 
accordingly, exhibited a higher biological activity (66.5±4.4%) as compared to lysozyme: 328 
Kollicoat® MAE 30 DP (1:4) (57.8±1.7%). Some literatures (e.g. (Vidal & Mello, 41)) have 329 
only focussed on the fact that the shift of Amide I band has a high impact on the protein 330 
biological activity. However, the results in this study exhibit the relevance of taking amide II 331 
into account when considering the analysis of protein bioactivity.   332 
Biological activity of lysozyme formulations before and after storage 333 
The biological activity of proteins is the most important aspect that reflects the success of any 334 
protein pharmaceutical formulation. Enzymatic activity assay measures the bioactivity of 335 
proteins that underwent dehydration stress and if the used excipients managed to protect the 336 
stability and integrity of the protein. Fig 4 displays the biological activity results of the 337 
reconstituted (freshly prepared , stored for 3 weeks at 7% RH at ČÇ ࡈ C (as solid form) and the 338 
heated aqueous samples to 50 °C for 30 min) lysozyme samples without and with excipients 339 
(Copovidone, Kollicoat® MAE 30 DP and Eudragit® RL PO). The biological activity of the 340 
reconstituted protein formulations was expressed as a percentage ± SD relevant to the 341 
unprocessed protein (the activity of unprocessed protein was 100%).  342 
Copovidone polymer, at both spray drying and freeze drying process, better maintained the 343 
biological activity and integrity of lysozyme after drying as compared with Kollicoat® MAE 344 
30 DP and Eudragit® RL PO. Spray drying and freeze drying of lysozyme with Copovidone 345 
maintained the lysozyme activity when was used at higher ratio (1:0.5) (101.6±2.2 and 346 
107.6±3.5%, respectively). Accordingly, the addition of Copovidone at 0.5 weight ratio had 347 
retained the bioactivity of lysozyme at 100% as compared to unprocessed lysozyme, and 348 
significantly (p<0.05) improved its bioactivity as compared to spray-dried lysozyme without 349 
excipients.  However, spray drying and freeze drying of lysozyme with Kollicoat® MAE 30 350 
DP and Eudragit® RL PO led to a significant (p<0.05) reduction of protein’s activity as 351 
compared to unprocessed protein. Copovidone (Fig1a) is a hygroscopic polymer which has a 352 
possible ability to stabilise proteins by forming hydrogen bonds with the oxygen molecules at 353 
the protein active site and stabilise these bonds through the carbonyl acetate groups and 354 
carbonyl pyrrolidinone groups in its structure. 355 
Lysozyme is considered as a relatively stable protein (thermally stable up to 75 șC), therefore 356 
to confirm the stabilising effects of the excipients, a sensitive protein (trypsin) was used in 357 
both spray dried and freeze dried forms with the same excipients and using same ratios as 358 
lysozyme to investigate this matter. The results were as follow: spray drying and freeze 359 
drying of trypsin with either Kollicoat® MAE 30 DP and Eudragit® RL led to horrendous 360 
reduction of trypsin biological activity (<30%). However, spray drying and freeze drying 361 
with Copovidone in both concentrations (0.2 and 0.5% w/v) significantly (p<0.05) helped to 362 
maintain more than 80% of trypsin biological activity (spray-dried trypsin with 0.2% w/w of 363 
Copovidone (94%), spray-dried trypsin with 0.5% w/w of Copovidone (87%), freeze-dried 364 
trypsin with 0.2% w/w of Copovidone (83%) and freeze-dried trypsin with 0.5% w/w of 365 
Copovidone (81%)). Accordingly, the effect of the used excipients was the same for both 366 
proteins (lysozyme and trypsin, which is more thermolabile compared to lysozyme). 367 
Lysozyme formulations were subjected to stability study. It was found that unprocessed 368 
lysozyme had lost ~19.8% of its bioactivity when stored at high relative humidity and ~15% 369 
at high temperature, as compared with the unprocessed lysozyme before storage (Fig 4). 370 
More than 90% of lysozyme biological activity was preserved for freeze-dried and spray-371 
dried lysozyme with Copovidone (using both weight ratios 1:0.2 and 1:0.5) compared to that 372 
of fresh protein formulations. Interestingly, the biological activity of protein was increased 373 
for freeze-dried lysozyme with Eudragit® RL PO.  374 
All samples showed a significant reduction of proteins activity upon storage at DĆࡈ C for 30min 375 
except for spray-dried and freeze-dried lysozyme with Copovidone, spray-dried and freeze-376 
dried lysozyme with 4% Kollicoat® MAE 30 DP and freeze-dried lysozyme with Eudragit® 377 
RL PO. This shows that these excipients help to rehydrate the protein and not just retain but 378 
improve its bioactivity during high temperature stress in contrary to protein samples without 379 
heating. DSC analysis showed similar results, Eudragit® RL PO and Kollicoat® MAE 30 DP 380 
have better thermal stability as they showed higher Tm compared to Copovidone samples 381 
which could indicate why Eudragit® RL PO and Kollicoat® MAE 30 DP had lower 382 
bioactivity without being subjected to heat stress and improved bioactivity after subjecting to 383 
thermal (50oC for 30 minutes) stress. This suggest that some excipients can tolerate heat and 384 
absorb heat stress, not the protein included with those excipients.  385 
A study by Dourado et al. (42) showed that Eudragit® L-100 which has a very similar 386 
chemical structure to the one used in this study (Kollicoat® MAE 30 DP) can form weak 387 
bound conjugates with proteins (38). Kollicoat® MAE 30 DP (Fig1b) contains several 388 
methyl groups in its molecular structure. It could possibly have been that Kollicoat® MAE 389 
30 DP due to their several methyl groups in their molecular structure bound to lysozyme’s 390 
hydrophobic pockets on the enzyme surface, stabilizing it and at the same time blocking the 391 
active site. When lysozyme’s active site is blocked, it diminishes its bioactivity unless 392 
unblocked again. And only when heated at 50 ºC for 30 minutes in aqueous solution, 393 
Eudragit® RL PO and Kollicoat® MAE 30 DP could have been hydrolysed off the enzyme 394 
releasing the enzyme and resulting in a higher bioactivity than the one before the heating.  395 
Kollicoat® MAE 30DP works by its pH dependant solubility. It is used for enteric coating 396 
tablets and dissolves at pH above 5.5. It is advised by the manufacturer (BASF) to be 397 
protected from heat and frost. This is probably the reason why increased the concentration of 398 
Kollicoat® MAE 30DP in the protein samples reduced the retained bioactivity when freeze-399 
dried. The pH of the phosphate buffer used in this study to dissolve the protein/Kollicoat® 400 
MAE 30DP mixture was higher than pH=5.5. It seems that Kollicoat® MAE 30DP has better 401 
high temperature tolerability than low temperature (during freeze drying).  402 
 403 
Conclusion 404 
Copovidone, a copolymer, significantly maintained the biological activity and conformation 405 
integrity of the protein as compared to Kollicoat® MAE 30DP and Eudragit® RL PO. Where 406 
spray drying and freeze drying of lysozyme with Copovidone preserved the lysozyme 407 
activity, when was used at the higher ratio (i.e. 1:0.5 protein:copolymer), at 100% as 408 
compared to unprocessed lysozyme, and significantly (p<0.05) improved protein bioactivity 409 
as compared to spray-dried lysozyme without excipients. 410 
Moreover, trypsin with Copovidone retained more than 80% of its biological activity after 411 
spray drying and freeze drying processes. Accordingly, the effect of the used excipients was 412 
the same for both proteins (lysozyme and trypsin). Therefore, it was concluded that 413 
Copovidone is a promising additive as it can preserve the integrity and activity of proteins 414 
using the two drying techniques. It is worth to be tried with more other proteins and with 415 
applying other formulating methods; such as protein crystallisation.  416 
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